Literature DB >> 2876135

Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway.

O Meirik, E Lund, H O Adami, R Bergström, T Christoffersen, P Bergsjö.   

Abstract

The possible association between oral contraceptive (OC) use and the risk of breast cancer developing before the age of 45 was investigated by means of a population based case-control study in Sweden and Norway. Information was obtained by personal interview from 422 (89.2%) of all eligible patients with a newly diagnosed breast cancer from May, 1984, to May, 1985, and from 722 (80.6%) of all contacted age-matched controls. A multivariate analysis, which accounted for several possible confounding factors, revealed a significant (p = 0.03) association between total duration of OC use and breast cancer risk. The relative risk (RR) of breast cancer after 12 or more years of OC use was 2.2 (1.2-4.0). OC use for more than 7 years before first full-term pregnancy entailed an increased breast cancer risk (RR = 2.0 [1.0-4.2]) which was of borderline significance. When total duration of use was considered, the risk of breast cancer was virtually unrelated to age at first OC use and latency from first use. The results suggest that long-term use of OCs may increase the risk of breast cancer in young women.

Entities:  

Keywords:  Breast Cancer; Cancer; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Developed Countries; Diseases; Europe; Family Planning; Neoplasms; Northern Europe; Norway; Oral Contraceptives--side effects; Population At Risk; Research Methodology; Scandinavia; Studies; Sweden

Mesh:

Substances:

Year:  1986        PMID: 2876135     DOI: 10.1016/s0140-6736(86)90166-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

Review 1.  Breast cancer hypothesis: a single cause for the majority of cases.

Authors:  R A Wiseman
Journal:  J Epidemiol Community Health       Date:  2000-11       Impact factor: 3.710

2.  Evaluation of a prescription based record-linkage model for epidemiological studies of long-term adverse effects of drugs--with special regard to combined oral contraceptives.

Authors:  I Persson; H O Adami; S E Norell; B Westerholm; B E Wiholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill?

Authors:  H Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  Recent oral contraceptive use and risk of breast cancer (United States)

Authors:  P A Newcomb; M P Longnecker; B E Storer; R Mittendorf; J Baron; R W Clapp; A Trentham-Dietz; W C Willett
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

5.  Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis.

Authors:  J Brind; V M Chinchilli; W B Severs; J Summy-Long
Journal:  J Epidemiol Community Health       Date:  1996-10       Impact factor: 3.710

6.  Depot medroxyprogesterone and risk of breast cancer.

Authors:  R H Gray
Journal:  BMJ       Date:  1989-10-28

7.  Oral contraceptive use and breast and ovarian cancer mortality in Switzerland.

Authors:  F Levi; F Gutzwiller; A Decarli; C La Vecchia
Journal:  J Epidemiol Community Health       Date:  1987-09       Impact factor: 3.710

8.  Cancer risks in perspective.

Authors:  P Reizenstein
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

9.  Oral contraceptive use and breast cancer risk among African-American women.

Authors:  J R Palmer; L Rosenberg; R S Rao; B L Strom; M E Warshauer; S Harlap; A Zauber; S Shapiro
Journal:  Cancer Causes Control       Date:  1995-07       Impact factor: 2.506

Review 10.  The relationship between oral contraceptive use, cancer and vascular disease.

Authors:  C La Vecchia; S Franceschi; P Bruzzi; F Parazzini; P Boyle
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.